Hep C Reinfection Observed in HIV-Positive Men Who Have Sex With Men
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 8, 2024 -- The incidence rate of hepatitis C virus (HCV) reinfection was 4.7 per 100 person-years among men who have sex with men (MSM) with HIV who cleared HCV, according to a study published online July 18 in Clinical Infectious Diseases.
Daniel S. Fierer, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a prospective cohort study involving MSM with HIV who cleared HCV to examine the incidence of and risk factors for HCV reinfection. The risk behaviors for primary HCV were assessed in New York City, including receipt of semen into the rectum and sexualized methamphetamine use, along with route of use.
The researchers found that 42 reinfections occurred over 898 person-years among 304 MSM with HIV who cleared HCV from 2000 through 2018, for an incidence rate of 4.7 per 100 person-years. Assessing 1,245 postclearance visits, there was only an association for receipt of semen into the rectum with reinfection (hazard ratio, 9.7), but no association was seen for methamphetamine use.
"We found the HCV reinfection rate to be an order of magnitude higher than the primary infection rate, similar to the findings from other cohorts in other countries," the authors write. "Condom use, the most effective currently available intervention to prevent semen ejaculation into the rectum, has not been successful as an HCV prevention strategy. Our results therefore suggest the need for novel interventions to prevent sexual transmission of HCV among MSM."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
FDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV Risk
FRIDAY, June 20, 2025 -- The U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to...
Anal Cancer Screening Cost-Effective for HIV+ Men Who Have Sex With Men ≥35 Years of Age
TUESDAY, June 17, 2025 -- For men who have sex with men (MSM) with HIV, aged 35 years or older, anal cancer screening is cost-effective, according to a study published online June...
Initiation of HIV PrEP in Young Adults Rose in Recent Years
TUESDAY, June 3, 2025 -- Dispensing and initiation of HIV preexposure prophylaxis (PrEP) among young adults increased from 2016 through 2023, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.